JCM, Vol. 12, Pages 1979: Autoimmune Hepatitis and Fibrosis

JCM, Vol. 12, Pages 1979: Autoimmune Hepatitis and Fibrosis

Journal of Clinical Medicine doi: 10.3390/jcm12051979

Authors: Rinaldo Pellicano Arianna Ferro Francesca Cicerchia Simone Mattivi Sharmila Fagoonee Marilena Durazzo

Autoimmune hepatitis (AIH) is a chronic immune-inflammatory disease of the liver, generally considered a rare condition. The clinical manifestation is extremely varied and can range from paucisymptomatic forms to severe hepatitis. Chronic liver damage causes activation of hepatic and inflammatory cells leading to inflammation and oxidative stress through the production of mediators. This results in increased collagen production and extracellular matrix deposition leading to fibrosis and even cirrhosis. The gold standard for the diagnosis of fibrosis is liver biopsy; however, there are serum biomarkers, scoring systems, and radiological methods useful for diagnosis and staging. The goal of AIH treatment is to suppress fibrotic and inflammatory activities in the liver to prevent disease progression and achieve complete remission. Therapy involves the use of classic steroidal anti-inflammatory drugs and immunosuppressants, but in recent years scientific research has focused on several new alternative drugs for AIH that will be discussed in the review.